Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy‐induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Davey, Kuchava, Vladimer, Bondarenko, Igor, Ivashchuk, Oleksandr, Reddy, Sreekanth, Jaal, Jana, Kudaba, Iveta, Hart, Lowell, Matitashvili, Amiran, Pritchett, Yili, Morris, Shannon R., Sorrentino, Jessica A., Antal, Joyce M., Goldschmidt, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048941/
https://www.ncbi.nlm.nih.gov/pubmed/33348420
http://dx.doi.org/10.1002/ijc.33453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048941/
https://www.ncbi.nlm.nih.gov/pubmed/33348420
http://dx.doi.org/10.1002/ijc.33453

Ejemplares similares